Zhu Y, et al. - In this retrospective analysis, researchers analyzed the impact of postoperative radiotherapy on individuals with stage IIIA(N2) non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation. For this investigation, they retrospectively analyzed 115 individuals diagnosed with stage IIIA(N2) resected NSCLC. Findings suggested that PORT could improve survival of patients with stage IIIA(N2) NSCLC. EGFR-mutant group with stage IIIA(N2) NSCLC had a tendency of a higher survival compared with the wild-type EGFR group, however, no significant difference was found for both groups. No association was found between the EGFR mutation status and progression free survival or overall survival of stage IIIA(N2) NSCLC.